贝伐珠单抗、雷珠单抗、阿柏西普与激光治疗早产儿视网膜病变后再治疗率的网状Meta分析
该网状Meta分析纳入30项研究共4686只眼,比较贝伐珠单抗、雷珠单抗、阿柏西普与激光作为早产儿视网膜病变(ROP)初始治疗后的再治疗率。1型ROP中激光单次治疗成功率89.3%,贝伐珠单抗87.0%,阿柏西普80.7%,雷珠单抗74.0%;贝叶斯网状Meta分析显示激光较雷珠单抗再治疗风险降低62%。I区ROP中贝伐珠单抗单次治疗成功率91.2%,雷珠单抗78.3%,激光65.9%;贝伐珠单抗较激光再治疗风险降低67%。
要点
- 1型ROP中激光单次治疗成功率89.3%,贝伐珠单抗87.0%,阿柏西普80.7%,雷珠单抗74.0%。
- 贝叶斯网状Meta分析显示激光较雷珠单抗再治疗风险降低62%(95%CrI 16%-83%)。
- I区ROP中贝伐珠单抗较激光再治疗风险降低67%(95%CrI 10%-90%)。
核心结论
- 1型ROP(I区和II区合并)中激光再治疗率低于雷珠单抗,而I区ROP中贝伐珠单抗再治疗率低于激光。
- 阿柏西普和贝伐珠单抗在ROP中显示的作用持续时间长于雷珠单抗。
研究设计与样本
- 检索CENTRAL、Embase、MEDLINE和CINAHL数据库至2022年3月,纳入随机对照试验和非随机比较研究。
- 纳入使用贝伐珠单抗、雷珠单抗、阿柏西普或激光治疗ROP且队列与治疗标准可比的研究,采用GRADE框架评价,排除病例选择有偏倚、非随机病例对照或无对照组的研究。
- 共30项研究(4686只眼)纳入网状Meta分析,采用频率学比例Meta分析确定各治疗方式的绝对再治疗率,采用贝叶斯网状Meta分析比较1型和I区ROP的治疗配对。
主要发现
- 1型ROP单次治疗成功率:激光89.3%(95%CI 83.8%-93.8%;n=1552),贝伐珠单抗87.0%(95%CI 78.6%-93.8%;n=2081),阿柏西普80.7%(95%CI 62.0%-94.4%;n=326),雷珠单抗74.0%(95%CI 62.7%-84.1%;n=727)。
- 贝叶斯网状Meta分析显示激光较雷珠单抗再治疗风险降低62%(95%CrI 16%-83%),其他配对比较无显著差异。
- 初次阿柏西普(12.96±0.47周)和贝伐珠单抗(11.36±0.54周)治疗后至二次治疗的时间显著长于初次雷珠单抗(9.29±0.43周)治疗(P=7×10⁻⁷和P=9×10⁻³)。
- I区ROP单次治疗成功率:贝伐珠单抗91.2%(95%CI 83.6%-96.9%;n=231),雷珠单抗78.3%(95%CI 61.4%-91.9%;n=100),激光65.9%(95%CI 41.4%-87.2%;n=158)。
- I区ROP贝叶斯网状Meta分析显示贝伐珠单抗较激光再治疗风险降低67%(95%CrI 10%-90%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: To compare bevacizumab, ranibizumab, aflibercept, and laser treatment as primary therapies for retinopathy of prematurity (ROP) in terms of retreatment rate. CLINICAL RELEVANCE: Anti-VEGF agents are increasingly used as primary treatment for ROP and may provide superior outcomes compared with laser in posterior disease. Head-to-head comparisons between different anti-VEGFs are lacking. METHODS: We searched CENTRAL, Embase, MEDLINE, and CINAHL databases for randomized controlled trials and nonrandomized comparative studies that had been reported as of March 2022. We included studies that used bevacizumab, ranibizumab, aflibercept or laser for ROP with comparable cohorts and treatment criteria. Studies were evaluated by the Grading of Recommendations, Assessment, Development and Evaluation framework, and those with biased case selection, nonrandomized case-control, or lack of control group were excluded. Frequentist meta-analyses of proportions determined the absolute primary retreatment rate of each modality and Bayesian network meta-analyses compared pairs of treatments in type 1 and Zone I ROP. RESULTS: In all, 30 studies (4686 eyes) were included in the network meta-analyses. For type 1 ROP, single-treatment success rates (i.e., likelihood of needing no further treatment) were 89.3% (95% confidence interval [CI]: 83.8%-93.8%; n = 1552) for laser, 87.0% (95% CI: 78.6%-93.8%; n = 2081) for bevacizumab, 80.7% (95% CI: 62.0%-94.4%; n = 326) for aflibercept, and 74.0% (95% CI: 62.7%-84.1%; n = 727) for ranibizumab. Bayesian network meta-analysis indicates that laser treatment is associated with a significant 62% (95% credible interval [CrI]: 16%-83%) reduction in retreatment risk compared with ranibizumab, while no significant difference was found among other pairwise comparisons. The mean ± standard error of the mean times to secondary treatment following primary aflibercept (12.96 ± 0.47 weeks) and bevacizumab (11.36 ± 0.54 weeks) therapy were significantly longer than that for primary ranibizumab (9.29 ± 0.43weeks) therapy (P = 7 × 10-7 and P = 9 × 10-3, respectively). For Zone I ROP, single-treatment success rates were 91.2% (95% CI: 83.6-96.9; n = 231) for bevacizumab, 78.3% (95% CI: 61.4-91.9; n = 100) for ranibizumab, and 65.9% (95% CI: 41.4-87.2; n = 158) for laser treatment. In this case, Bayesian network meta-analysis suggests that primary bevacizumab is associated with a significant 67% (95% CrI:10%-90%) reduction in retreatment risk compared with laser treatment. CONCLUSIONS: Laser was associated with a lower rate of retreatment than ranibizumab in type 1 ROP (Zones I and II combined), while bevacizumab was associated with a lower rate of retreatment than laser in Zone I ROP. Aflibercept and bevacizumab demonstrate longer duration of action than ranibizumab for ROP.
引用
- Chang E, Josan AS, Purohit R, et al. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity. Ophthalmology. 2022. PMID: 35842190. doi:10.1016/j.ophtha.2022.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。